Imfinzi + Imjudo recommended for approvals in EU
19 December 2022 07:10 GMT Imfinzi plus Imjudo recommended for approval in the EU by CHMP for the treatment of advanced liver and lung cancers Positive opinions based on significant survival benefit in HIMALAYA and POSEIDON Phase III trials AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) combinations have been recommended for marketing authorisation in the European Union (EU) for advanced liver and lung cancers. The concurrent positive opinions recommend authorising Imfinzi in combination with Imjudo for 1st-line treatment of adult patients with advanced or